SaveHealth reports migraines are complex neurological conditions affecting over a billion globally, requiring comprehensive ...

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) ...

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

A structured approach to exercise, diet, brain training, social engagement and clinical testing yielded greater cognitive ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...